Advertisement
U.S. markets closed

ProPhase Labs, Inc. (PRPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.14+0.10 (+1.98%)
At close: 04:00PM EDT
5.29 +0.15 (+2.92%)
After hours: 07:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Engulfing Line (Bearish)

Engulfing Line (Bearish)

Previous Close5.04
Open4.89
Bid4.81 x 1400
Ask5.00 x 1200
Day's Range4.89 - 5.35
52 Week Range4.05 - 9.94
Volume50,771
Avg. Volume24,348
Market Cap92.751M
Beta (5Y Monthly)-0.33
PE Ratio (TTM)N/A
EPS (TTM)-0.63
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 24, 2022
1y Target Est15.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
14% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PRPH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ProPhase Labs, Inc.
    JBSS: Raising target price to $108.00JOHN B. SANFILIPPO & SON INC has an Investment Rating of HOLD; a target price of $108.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Insider Monkey

    ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call Transcript

    ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call Transcript March 15, 2024 ProPhase Labs, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $-0.27. PRPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Noella Alexander-Young: Hello, and good […]

  • GlobeNewswire

    Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)

    NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on the ProPhase’s business model, services, industry, financial results, valuation, and risks. The update note is available here. Highlights from the note include: FY 2023 Financial Results Update: For the fiscal year ending December 31, 2023

  • GlobeNewswire

    ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

    Nebula Genomics secures major international B2B deal – Additional significant B2B deals in final stages Ahead of schedule, Pharmaloz Manufacturing accelerates capacity expansion – set for rapid revenue and profit growth Completes full transition and right sized operation in Q4 from clinical lab to cutting edge genomics lab Company to hold a conference call Friday March 15, 2024, at 11:00 AM ET Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or t